#news #biotech Pfizer’s abrocitinib beats blockbuster Dupixent in phase 3 eczema trial, but key questions remain

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Pfizer’s abrocitinib beats blockbuster Dupixent in phase 3 eczema trial, but key questions remain .Pfizer’s abrocitinib beats blockbuster Dupixent in phase 3 eczema trial, but key questions remain
ntaylor
Mon, 08/30/2021 – 08:44

from FierceBiotech: Biotech https://ift.tt/3BgcYzM